PARP1 inhibitors (PARPi), including olaparib (LYNPARZA), niraparib (ZEJULA) and rucaparib (RUBRACA), are recommended for the maintenance of care in patients with recurrent ovarian cancer due to improved benefits and fewer adverse reactions in patients with a full or partial platinum-based chemotherapy response [12,13,14,15,16]. This evidence concerns the gene PARP1 and ovarian carcinoma.